| Entry |
|
| Name |
Nogapendekin alfa inbakicept; Nogapendekin alfa inbakicept-pmln; Anktiva (TN) |
| Product |
|
| Component |
|
| Remark |
|
| Efficacy |
Antineoplastic, IL-15 receptor agonist |
| Disease |
|
| Comment |
Complex of Nogapendekin alfa [DR: D11821] and inbakicept [DR: D11747]
|
| Target |
|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04672 | Intestinal immune network for IgA production |
|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L03 IMMUNOSTIMULANTS
L03A IMMUNOSTIMULANTS
L03AC Interleukins
L03AC03 Nogapendekin alfa and inbakicept
D12888 Nogapendekin alfa inbakicept <US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastics, Other
Antineoplastics, Miscellaneous
Nogapendekin Alfa Inbakicept
D12888 Nogapendekin alfa inbakicept
Target-based classification of drugs [BR:br08310]
Signaling molecules and receptors
Cytokine receptors
Interleukin receptors
IL15RA (CD215)
D12888 Nogapendekin alfa inbakicept <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12888
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D12888
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12888
|
| Other DBs |
|